Navigation Links
Massachusetts General study defines a new genetic subtype of lung cancer
Date:1/31/2012

A report from investigators at the Massachusetts General Hospital (MGH) Cancer Center has defined the role of a recently identified gene abnormality in a deadly form of lung cancer. Tumors driven by rearrangements in the ROS1 gene represent 1 to 2 percent of non-small-cell lung cancers (NSCLC), the leading cause of cancer death in the U.S. The researchers show that ROS1-driven tumors can be treated with crizotinib, which also inhibits the growth of tumors driven by an oncogene called ALK, and describe the remarkable response of one patient to crizotinib treatment.

"ROS1 encodes a protein that is important for cell growth and survival, and deregulation of ROS1 through chromosomal rearrangement drives the growth of tumors," says Alice Shaw, MD, PhD, of the MGH Cancer Center co-lead author of the paper which has been published online in the Journal of Clinical Oncology. "This finding is important because we have drugs that inhibit ROS1 and could lead to the sort of dramatic clinical response we describe in this paper."

The current findings add ROS1 to the list of genes known to drive NSCLC growth when altered a list that includes KRAS, mutations of which account for about 25 percent of cases; EGFR, accounting for 10 to 15 percent; and ALK, rearranged in about 4 percent. Altogether, known cancer-causing genetic changes have been found in a little more than half of NSCLC tumors. Originally identified in brain tumors, ROS1 rearrangement previously had been identified in one NSCLC patient and one NSCLC cell line. The current study was designed to determine the frequency of ROS1 rearrangement in NSCLC and to define the characteristics of patients with ROS1-rearranged tumors.

The investigators screened tumor samples from more than 1,000 NSCLC patients treated at the MGH, Vanderbilt University, the University of California at Irvine, and Fudan University in Shanghai, China. ROS1 rearrangement was identified in 18 tumor samples, for a prevalence of 1.7 percent; ALK rearrangements were identified in 31 samples, with no samples showing alterations in both genes. Patients with ROS1-positive tumors tended to be younger, never to have smoked and to have a type of lung cancer called adenocarcinoma characteristics very similar to those of ALK-positive patients.

An earlier MGH study of an experimental ALK inhibitor had found the drug suppressed the growth of a ROS1-positive cell line in addition to ALK-positive cell lines, suggesting that ROS1-positive tumors might be sensitive to the ALK-inhibitor crizotinib. This observation led corresponding author John Iafrate, MD, PhD, and his team to develop a diagnostic test that could identify ROS1-positive tumors. Around the time that test became clinically available, a lung cancer patient whose tumor had not responded to drugs targeting EGFR mutations was referred to the MGH Cancer Center for genetic testing. His tumor was negative for ALK but later proved to harbor a ROS1 rearrangement, and he was enrolled in an extension of the crizotinib clinical trial first reported in the October 28, 2010, New England Journal of Medicine.

"When he enrolled in the trial last April, this patient was extremely sick with significant weight loss and very low oxygen levels and was barely able to walk," says Shaw. "Within a few days of starting crizotinib, he felt better; and by the time we scanned his chest at seven weeks, the tumors had essentially disappeared from his lungs." Nine months after starting crizotinib therapy, this patient continues to do well. Additional ROS1-positive patients have been enrolled in this trial at MGH, at UC Irvine and at the University of Colorado.


'/>"/>
Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Rutgers, Massachusetts General investigators find novel way to prevent drug-induced liver injury
2. Even privately insured have hard time getting psychiatric care in Massachusetts: Harvard study
3. Massachusetts health-care reform increased access to care, particularly among disadvantaged
4. Massachusetts General Hospital, Iacocca Foundation announce promising results of Phase I diabetes trial
5. Study examines impact of Massachusetts health law on emergency department visits
6. Support for Massachusetts landmark health reform law rises in 2011
7. Massachusetts Study Shows Sharp Rise in Early Autism Diagnoses
8. Season of birth and celiac disease in Massachusetts children
9. Massachusetts reform hasnt stopped medical bankruptcies: Harvard study
10. Massachusetts General Hospital leading nationwide, comparative study of common bipolar medications
11. Massachusetts physician groups improving patient experience, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 23, 2017 , ... Sharon Kleyne, host of the nationally syndicated radio program, ... VoiceAmerica, recently talked on her program about how she is looking forward to World ... of an important distinction. World Water Day, Kleyne pointed out, is an occasion for ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! ... thinking about summer internships , which can be frustrating when they don’t even ... Garden Media Group, a boutique public relations firm outside of Philadelphia, have offered these ...
(Date:3/23/2017)... New Port Richey, FL (PRWEB) , ... March 23, 2017 , ... ... delighted to announce that 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health ... that ABQAURP honors those who have contributed not only to the association, but also ...
(Date:3/23/2017)... ... March 23, 2017 , ... On 2 March 2017, ... US Special Operations Command’s Patriot Award. The award was presented by the USSOCOM ... Dagger Foundation for its significant and enduring support to the command. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare Solutions unveils the ... 21st annual Compliance Institute on March 26-28 in National Harbor, Maryland. ... chart types with a comprehensive set of features including built-in workflow, interactive audit ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... Pennsylvania , 22 de marzo de 2017 ... independiente global líder de soluciones de productos y ... anunciado hoy que ha adquirido EPL Archives, Inc., ... a los clientes en todo el ciclo de ... comercialización ofreciendo una muestra de archivo, almacenamiento de ...
(Date:3/22/2017)... March 22, 2017 Under the impetus ... packaging market size increased year by year at ... to 2021, the market size will maintain the ... to outnumber RMB140 billion in 2021, thanks to ... development of biological agents and supporting policies. ...
(Date:3/22/2017)... 22. März 2017   VWR ... tätige Anbieter von Produkten und Dienstleistungen für ... von EPL Archives Inc. bekannt, eines internationalen ... im kompletten Zyklus regulierter Forschung, Entwicklung und ... Speicherung von Dokumenten und Zusatzdienstleistungen zur Seite ...
Breaking Medicine Technology: